Levosimendan to Reduce Mortality in High Risk Cardiac Surgery Patients. A Multicentre Randomized Controlled Trial

Trial Profile

Levosimendan to Reduce Mortality in High Risk Cardiac Surgery Patients. A Multicentre Randomized Controlled Trial

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Cardiovascular disorders; Low cardiac output
  • Focus Therapeutic Use
  • Acronyms CHEETAH
  • Most Recent Events

    • 21 Jul 2016 Status changed from recruiting to completed.
    • 01 Jul 2016 Trial design published in the American Heart Journal
    • 28 Nov 2012 Planned number of patients added to 1000 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top